Aggressive Treg-Modulating Immunology Strategy and Advancing Clinical Execution Underpin Buy Rating on Coya in ALS and FTD

Analyst Thomas Shrader of BTIG maintained a Buy rating on Coya Therapeutics, Inc., retaining the price target of $16.00.

Thomas Shrader has given his Buy rating due to a combination of factors including Coya’s differentiated strategy in ALS and FTD and the strength of early clinical signals. He highlights that restoring Treg function combined with CTLA4 modulation represents a particularly aggressive, high‑impact immunology approach, with initial data in both ALS and frontotemporal dementia showing unexpectedly robust clinical stability and biomarker improvements relative to the rapid decline typically seen in these diseases.

He also notes the advancing clinical execution, with the ALSTARS Phase 2 ALS trial enrolling across a broad U.S. and Canadian site network, added credibility from NEALS affiliation and Health Canada approval, and a second major indication in FTD now cleared by the FDA. In addition, a clean safety profile, supportive preclinical anti‑inflammatory data from COYA 303, upcoming biomarker readouts that could de‑risk the program ahead of topline results, and a discounted‑cash‑flow valuation that suggests upside versus the current share price all support his positive stance on the stock.

In another report released yesterday, Chardan Capital also maintained a Buy rating on the stock with a $14.00 price target.

COYA’s price has also changed moderately for the past six months – from $5.670 to $4.500, which is a -20.63% drop .